Articles tagged with Cancer Immunotherapy
Researchers engineered CAR T cells to produce a fusion of IL-12 cytokine and a PD-L1 blocker, boosting immune activity against solid tumors. The modified cells were found to be highly effective in shrinking ovarian and prostate tumors while minimizing side effects.
The research team developed multifunctional nanocomposites that demonstrate excellent tumor-targeting capability through the EPR effect. Irradiation with near-infrared laser light achieved multidimensional therapeutic effects, including complete elimination of transplanted mouse cancers within 5 days.
Researchers identified genetic modifications that can improve the efficacy of chimeric antigen receptor (CAR)-T cell treatment for multiple myeloma and other cancers. The study used CRISPR screening to pinpoint genes that influenced T cell function and survival in culture and in a preclinical model of multiple myeloma.
Recent clinical trials demonstrate the potential benefits of neoadjuvant chemotherapy and immunotherapy in improving tumor response and surgical success for patients with locally advanced colon cancer. The approach also reduces the risk of recurrence and metastasis, increasing survival outcomes and decreasing cancer-related complications.
Researchers developed a fusion protein that blocks the 'do not attack' signal and selectively activates tumor-fighting immune cells. The molecule, combining an IL-2 variant with a PD-1 antibody, induces a multifaceted anti-tumoral T cell response in human lung cancer patients.
Research has shown that lymph nodes provide the right environment for stem-like T cells to survive, multiply, and produce killer cells. Preserving lymph nodes could strengthen immune responses and increase the effectiveness of immunotherapy. The study's findings have important implications for cancer therapy.
The researchers developed a novel cell-surface protein engineering strategy called PATCH, which applies proximity labeling to immunomodulation for the first time. This approach directly amplifies targeting signals on the tumor cell surface, identifying cells that need to be attacked by the immune system.
UCSF researchers develop a new strategy to prime CAR T cell therapy by combining it with diabetes drugs, increasing the efficacy of NECTIN4-CAR T cells in treating urothelial carcinoma. The study shows that using thiazolidinediones enhances NECTIN4 expression, making tumor cells more susceptible to the treatment.
Researchers found that lung tumors reshape immune cells in the bone marrow before they reach the cancer, altering their function and leading to a stronger anti-cancer response. The study identified NRF2 as a key protein involved in this process and proposed blocking it as a potential strategy to enhance immunotherapy.
A clinical trial found that patients with mesothelioma who received combination immunotherapy drugs before surgery had successful surgeries and improved early outcomes. The study showed that tracking tumor DNA in the blood could help predict treatment benefit.
DZ-002 is an innovative cancer treatment developed through a collaborative effort among Georgia State University, Emory University and Cedars-Sinai Medical Center. The technology harnesses targeted radiation to destroy tumors with precision, offering hope for improved patient outcomes.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
A study led by Yibin Kang and Yujiao Han reveals that cancer cells hijack a specialized cell to recycle iron, depriving red blood cells of necessary iron and causing anemia. The discovery aims to slow down bone metastasis and alleviate complications.
A team of scientists has developed a protein-based therapeutic tool called Crunch to target and remove specific living cells, such as cancer cells or overactive immune cells. The new system uses the body's natural waste removal system to clear out unwanted cells, offering hope for improved treatments.
A study published in Cell Reports Medicine found that zeaxanthin, a plant-derived carotenoid, strengthens the activity of immune cells that kill tumor cells. The findings suggest that zeaxanthin could complement and strengthen advanced cancer treatments like immunotherapy.
Researchers mapped the surface envelope glycoprotein of human endogenous retroviruses, opening doors to new diagnostic and therapeutic opportunities. The study revealed specific antibodies that target the viral proteins, potentially leading to new cancer immunotherapies and treatments for autoimmune diseases.
Researchers at Purdue University have developed a new method to study biochemical processes that impair the immune system's ability to recognize and kill cancer cells. The method involves tracking RNA-binding proteins and extracellular vesicles, which can compromise immunotherapy.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers found that cancer cells break down nerve protective covers, triggering chronic inflammation and immune exhaustion, making treatment resistant. Targeting the nerve injury pathway can reverse this resistance and improve treatment response.
A recent study published in Nature Communications provides a comprehensive characterization of Large Cell Neuroendocrine Carcinoma (LCNEC), a rare and aggressive type of lung cancer. The research team analyzed data from 590 patients and found that LCNEC shares features with other types of lung cancer, yet has distinct aspects. They ide...
In a phase 1 clinical trial, the engineered antibody improved a class of drugs that had struggled to deliver on its early promise. Six patients experienced systemic tumor reduction, including two complete responses, with minimal side effects.
A team of researchers has visualized the nanoscale architecture of CD20 receptors and their interactions with anti-CD20 antibodies using a novel super-resolution microscopy technique. The study reveals that structural changes in antibody design translate into different receptor patterns and cellular responses, opening up new pathways f...
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers at La Jolla Institute for Immunology examine how genetics, sex hormones, and environmental factors shape the immune system. Women have a stronger immune response due to their XX chromosomes and estrogen, but also face an increased risk of autoimmune diseases.
Research suggests that consuming high levels of sucralose can make cancer treatment less effective by disrupting the gut microbiome and altering T cell function. However, adding arginine or citrulline supplements to the diet may restore immunotherapy effectiveness in patients with melanoma and non-small cell lung cancer.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.
A new study found that immunotherapy may change the bone marrow environment where cancer cells live, potentially helping the immune system respond more effectively. Researchers tracked how the immune system interacts with cancer cells after treatment and noticed changes in cellular neighborhoods and cell communication.
Researchers developed a new AI model named BATMAN to improve T cell receptor therapy accuracy. The AI uses a vast database of over 22,000 TCR-peptide interactions to predict peptide binding and identify potential cancer treatments.
A plant virus, cowpea mosaic virus (CPMV), has shown promise as a low-cost and potent cancer immunotherapy. CPMV stimulates type I, II, and III interferons, which have well-known anti-cancer properties, and activates toll-like receptor 7 to prime antiviral and anti-tumor immune responses.
Researchers found that certain antibodies can reduce antitumor immune cells, highlighting the need to consider ADCC activity when designing or selecting ICI therapeutics. This study could help improve cancer treatment by engineering antibodies that avoid damaging essential immune cells.
A study published in Nature found that autoantibodies can tilt the odds dramatically toward shrinking tumors and enhance the effectiveness of immunotherapy. Certain autoantibodies linked to better clinical outcomes could reveal cancer's weak spots and point to new targets for treatment.
Researchers have discovered an experimental mRNA vaccine that can boost tumor-fighting effects of immunotherapy, sparking a new approach to battling many types of treatment-resistant tumors. The study found that pairing the test vaccine with common anticancer drugs triggered a strong antitumor response.
Researchers developed a biomimetic physical barrier that temporarily blocks T cell-tumor cell interactions, delaying exhaustion and enabling a stronger immune response. The breakthrough strategy can potentially be combined with other immunotherapeutic approaches to enhance treatment efficacy.
The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
A new study from Uppsala University found that most men with prostate cancer who receive recommended treatment have a good prognosis, with a lower risk of dying from prostate cancer than other causes. The study's findings highlight the importance of assessing a patient's life expectancy in choosing an appropriate treatment strategy.
Researchers developed a novel immunotherapy that disrupts the IL-33/IL1RL1 signaling loop to boost immune function and improve survival in leukemia patients. The treatment targeted leukemia stem cells, reducing relapse rates and improving survival without major side effects.
A new study published in the Journal of Hepatology shows that durvalumab plus GemCis significantly improves overall survival for patients with advanced biliary tract cancer. The three-year follow-up analysis found that over twice as many participants treated with durvalumab plus GemCis remained alive compared to those treated with a pl...
A Phase II study found that 87% of patients with stage III melanoma remained alive and disease-free four years after treatment with nivolumab and relatlimab. Researchers identified unique biomarkers associated with better outcomes, including high TIGIT levels and low B7-H3 levels.
A new study from the University of Pittsburgh shows exercise improves cancer outcomes and enhances response to immunotherapy in mice by reshaping the gut microbiome. The research found that a specific compound called formate, produced by gut bacteria in exercised mice, was associated with better outcomes in patients with melanoma.
Researchers identify new group of immune cells driving autoimmune attack on insulin-producing cells in pancreas during cancer immunotherapy. JAK inhibitors, already FDA-approved for psoriasis and arthritis, show potential to prevent and even reverse type 1 diabetes in preclinical models.
A new dual CAR-T cell therapy has been developed to target T-ALL, showing high efficacy and safety. The treatment targets two antigens simultaneously, making it more effective than previous therapies. Experimental results demonstrate its ability to control the disease in both laboratory and animal models, with an excellent safety profile.
Researchers have identified a single genetic difference in Fas Ligand, an immune protein, that makes it vulnerable to being disabled by plasmin, a tumor-associated enzyme. This vulnerability seems unique to humans and may contribute to the effectiveness of certain cancer treatments.
Scientists have developed a miniature device that mimics human bone marrow and immune environment, enabling predictive testing of cancer immunotherapy success in patients. The device recreates three regions of bone marrow where leukemia develops and retains the complex immune environment of the tissue.
Scientists have discovered that CD4 T cells can target tumour cells with high efficiency, expanding the pool of patients who could benefit from this therapy. A clinical trial is currently preparing to test this approach in adults and children with various types of cancer.
This study identifies pre-neadjuvant carcinoembryonic antigen (CEA) and neutrophil-to-lymphocyte ratio (NLR) as significant predictors of postoperative recurrence-free survival in non-small cell lung cancer (NSCLC) patients after neoadjuvant therapy. Smoking history is also a predictor of recurrence in LUSC patients.
The new NCCN Guidelines Navigator tool offers an interactive platform for accessing evidence-based guidelines, facilitating easier searching and navigation. The initiative aims to improve patient care and outcomes by providing healthcare professionals with up-to-date recommendations.
A new study reveals that cancer-fighting immunotherapy drugs may offer benefits to organ transplant recipients with advanced cancer when carefully managed. The study found that about one in three patients responded positively to treatment within a year, with improved survival outcomes comparable to the general population.
The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.
CIK cell therapy improved overall and progression-free survival for patients with colorectal cancer, regardless of disease stage. Serum CEA levels can predict treatment response, paving the way for a simple blood test.
Researchers at MD Anderson have made significant progress in treating non-small cell lung cancer (NSCLC) by combining chemotherapy, immunotherapy, and surgery. They found that pre-surgical combination therapy showed promising results, with high rates of pathological complete response and major pathological response.
Researchers at Nagoya University have created CAR-T cells that recognize and target the Eva1 protein on cancer cells, effectively eliminating tumors in lab mice. The treatment is designed to be safer by ignoring healthy cells with low amounts of Eva1.
Researchers at NYU Langone Health discovered that a specific biological pathway explains why many patients with deadly melanoma do not respond to latest cancer treatments. The study found therapeutic targets that could limit melanoma growth in patients with NF1 mutations, suggesting a novel approach for treatment.
A recent study found that MET mutations are associated with enhanced tumor immunogenicity, increased immune cell infiltration, and improved response rates to immune checkpoint blockade. Certain single base substitutions identified as robust predictive biomarkers for survival in pan-cancer immunotherapy.
Researchers found a specific genetic mutation, MT haplogroup T, in patients who did not respond to immune checkpoint inhibitors. The study showed that these patients had more underdeveloped T cells and increased resilience to reactive oxygen species, stunting their attack on cancer cells.
Researchers identified a link between the loss of Y chromosome in white blood cells and reduced ability to kill cancer cells. This finding may explain why men with loss of Y have higher cancer risks and poorer outcomes. The study provides insights into how this genetic change affects immune system function.
Combining immunotherapy drug dostarlimab with standard chemotherapy improved survival and reduced symptoms in patients with advanced endometrial cancer. Patients lived up to 5.5 months longer with fewer side effects, outweighing risks.
A global clinical trial led by Irish cancer specialist Prof. Patrick Forde shows that immunotherapy with chemotherapy before lung cancer surgery reduces the risk of cancer returning and improves long-term survival. The study found that patients who received immunotherapy plus chemotherapy had improved outcomes compared to those who rec...
A new study found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer resulted in a 50% reduction in cancer recurrence and death compared to chemotherapy alone. The treatment combination showed significant benefits for patients with deficient DNA mismatch repair genetic makeup.
A phase I clinical trial demonstrates that dual-target CAR T cell therapy can reduce tumor size in nearly two-thirds of patients with recurrent glioblastoma, a notoriously aggressive brain cancer. The therapy also shows signs of long-term immune system activation and potential for extended tumor stability.